Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Helena Raquel is active.

Publication


Featured researches published by Helena Raquel.


Blood | 2010

The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to γδ T-cell cytotoxicity

Telma Lança; Daniel V. Correia; Catarina Moita; Helena Raquel; Ana Neves-Costa; Cristina Ferreira; José S. Ramalho; João T. Barata; Luis F. Moita; Anita Q. Gomes; Bruno Silva-Santos

On the path to successful immunotherapy of hematopoietic tumors, gammadelta T cells offer great promise because of their human leukocyte antigen (HLA)-unrestricted targeting of a wide variety of leukemias/lymphomas. However, the molecular mechanisms underlying lymphoma recognition by gammadelta T cells remain unclear. Here we show that the expression levels of UL16-binding protein 1 (ULBP1) determine lymphoma susceptibility to gammadelta T cell-mediated cytolysis. Consistent with this, blockade of NKG2D, the receptor for ULBP1 expressed on all Vgamma9(+) T cells, significantly inhibits lymphoma cell killing. Specific loss-of-function studies demonstrate that the role of ULBP1 is nonredundant, highlighting a thus far unique physiologic relevance for tumor recognition by gammadelta T cells. Importantly, we observed a very wide spectrum of ULBP1 expression levels in primary biopsies obtained from lymphoma and leukemia patients. We suggest this will impact on the responsiveness to gammadelta T cell-based immunotherapy, and therefore propose ULBP1 to be used as a leukemia/lymphoma biomarker in upcoming clinical trials.


Immunity | 2013

Anthracyclines induce DNA damage response-mediated protection against severe sepsis.

Nuno Figueiredo; Angelo Chora; Helena Raquel; Nadja Pejanovic; Pedro Pereira; Björn Hartleben; Ana Neves-Costa; Catarina Moita; Dora Pedroso; Andreia Pinto; Sofia Marques; Hafeez Faridi; Paulo Costa; Raffaella Gozzelino; Jimmy L. Zhao; Miguel P. Soares; Margarida Gama-Carvalho; Jennifer Martinez; Qingshuo Zhang; Gerd Döring; Markus Grompe; J. Pedro Simas; Tobias B. Huber; David Baltimore; Vineet Gupta; Douglas R. Green; João Ferreira; Luis F. Moita

Severe sepsis remains a poorly understood systemic inflammatory condition with high mortality rates and limited therapeutic options in addition to organ support measures. Here we show that the clinically approved group of anthracyclines acts therapeutically at a low dose regimen to confer robust protection against severe sepsis in mice. This salutary effect is strictly dependent on the activation of DNA damage response and autophagy pathways in the lung, as demonstrated by deletion of the ataxia telangiectasia mutated (Atm) or the autophagy-related protein 7 (Atg7) specifically in this organ. The protective effect of anthracyclines occurs irrespectively of pathogen burden, conferring disease tolerance to severe sepsis. These findings demonstrate that DNA damage responses, including the ATM and Fanconi Anemia pathways, are important modulators of immune responses and might be exploited to confer protection to inflammation-driven conditions, including severe sepsis.


Autoimmunity Reviews | 2012

Effective treatment of rat adjuvant-induced arthritis by celastrol

Rita Cascão; Bruno Vidal; Helena Raquel; Ana Neves-Costa; Nuno Figueiredo; Vineet Gupta; João Eurico Fonseca; Luis F. Moita

We have previously reported an increase in interleukin (IL)-1β and IL-17 levels, and a continuous activation of caspase-1 in early rheumatoid arthritis (RA) patients. These results suggest that drugs targeting IL-1β regulatory pathways, in addition to tumor necrosis factor (TNF), may constitute promising therapeutic agents in early RA. We have recently used a THP-1 macrophage-like cell line to screen 2320 compounds for those that down-regulate both IL-1β and TNF secretion. Celastrol was one of the most promising therapeutic candidates identified in that study. Our main goal in the present work was to investigate whether administration of celastrol is able to attenuate inflammation in a rat model of adjuvant-induced arthritis (AIA). Moreover, since IL-1β is known to play a role in the polarization of Th17 cells, we also investigate whether administration of digoxin, a specific inhibitor of Th17 cells polarization, is able to attenuate inflammation in the same rat model. We found that celastrol administration significantly suppressed joint inflammation. The histological and immunohistochemical evaluation revealed that celastrol-treated rats had a normal joint structure with complete abrogation of the inflammatory infiltrate and cellular proliferation. In contrast, we observed that digoxin administration significantly ameliorated inflammation but only if administrated in the early phase of disease course (after 4days of disease induction), and it was not efficient at inhibiting the infiltration of immune cells within the joint and in preventing damage. Thus, our results suggest that celastrol has significant anti-inflammatory and anti-proliferative properties and can constitute a potential anti-inflammatory drug with therapeutic efficacy in the treatment of immune-mediated inflammatory diseases such as RA. Furthermore, we find that early inhibition of Th17 cells polarization ameliorates arthritis but it is not as effective as celastrol.


PLOS ONE | 2012

Highly Dynamic Host Actin Reorganization around Developing Plasmodium Inside Hepatocytes

Carina S. S. Gomes-Santos; Maurice A. Itoe; Cristina Afonso; Ricardo Henriques; Rui Gardner; Nuno Sepúlveda; Pedro D. Simões; Helena Raquel; Antonio Almeida; Luis F. Moita; Friedrich Frischknecht; Maria M. Mota

Plasmodium sporozoites are transmitted by Anopheles mosquitoes and infect hepatocytes, where a single sporozoite replicates into thousands of merozoites inside a parasitophorous vacuole. The nature of the Plasmodium-host cell interface, as well as the interactions occurring between these two organisms, remains largely unknown. Here we show that highly dynamic hepatocyte actin reorganization events occur around developing Plasmodium berghei parasites inside human hepatoma cells. Actin reorganization is most prominent between 10 to 16 hours post infection and depends on the actin severing and capping protein, gelsolin. Live cell imaging studies also suggest that the hepatocyte cytoskeleton may contribute to parasite elimination during Plasmodium development in the liver.


Mediators of Inflammation | 2014

Potent Anti-Inflammatory and Antiproliferative Effects of Gambogic Acid in a Rat Model of Antigen-Induced Arthritis

Rita Cascão; Bruno Vidal; Helena Raquel; Ana Neves-Costa; Nuno Figueiredo; Vineet Gupta; João Eurico Fonseca; Luis F. Moita

Background. We have previously reported a continuous activation of caspase-1 and increased interleukin (IL)-1β levels in early rheumatoid arthritis (RA). These observations raised the hypothesis that drugs targeting the IL-1β pathway, in addition to tumour necrosis factor (TNF), may be particularly effective for early RA treatment. We have recently identified gambogic acid as a promising therapeutic candidate to simultaneously block IL-1β and TNF secretion. Our main goal here was to investigate whether gambogic acid administration was able to attenuate inflammation in antigen-induced arthritis (AIA) rats. Methods. Gambogic acid was administered to AIA rats in the early and late phases of arthritis. The inflammatory score, ankle perimeter, and body weight were evaluated during the period of treatment. Rats were sacrificed after 19 days of disease progression and paw samples were collected for histological and immunohistochemical evaluation. Results. We found that inflammation in joints was significantly suppressed following gambogic acid administration. Histological and immunohistochemical evaluation of treated rats revealed normal joint structures with complete abrogation of the inflammatory infiltrate and cellular proliferation. Conclusions. Our results suggest that gambogic acid has significant anti-inflammatory properties and can possibly constitute a prototype anti-inflammatory drug with therapeutic efficacy in the treatment of inflammatory diseases such as RA.


PLOS ONE | 2011

An shRNA-Based Screen of Splicing Regulators Identifies SFRS3 as a Negative Regulator of IL-1β Secretion

Pedro Moura-Alves; Ana Neves-Costa; Helena Raquel; Teresa R. Pacheco; Bruno D'Almeida; Raquel Rodrigues; Iris Cadima-Couto; Ângelo Chora; Mariana Oliveira; Margarida Gama-Carvalho; Nir Hacohen; Luis F. Moita

The generation of diversity and plasticity of transcriptional programs are key components of effective vertebrate immune responses. The role of Alternative Splicing has been recognized, but it is underappreciated and poorly understood as a critical mechanism for the regulation and fine-tuning of physiological immune responses. Here we report the generation of loss-of-function phenotypes for a large collection of genes known or predicted to be involved in the splicing reaction and the identification of 19 novel regulators of IL-1β secretion in response to E. coli challenge of THP-1 cells. Twelve of these genes are required for IL-1β secretion, while seven are negative regulators of this process. Silencing of SFRS3 increased IL-1β secretion due to elevation of IL-1β and caspase-1 mRNA in addition to active caspase-1 levels. This study points to the relevance of splicing in the regulation of auto-inflammatory diseases.


Plant Biotechnology Reports | 2008

Expression of prune dwarf Ilarvirus coat protein sequences in Nicotiana benthamiana plants interferes with PDV systemic proliferation

Helena Raquel; Tiago Lourenço; Catarina Moita; M. Margarida Oliveira

Prune dwarf virus (PDV) is an Ilarvirus systemically infecting almond trees and other Prunus species and spreading through pollen, among other means. We have studied strategies based on coat protein (cp) gene to block PDV replication in host plant cells. A Portuguese isolate of PDV was obtained from infected almond leaves and used to produce the cDNA of the cp gene. Various constructs were prepared based on this sequence, aiming for the transgenic expression of the original or modified PDV coat protein (cpPDVSense and cpPDVMutated) or for the expression of cpPDV RNA (cpPDVAntisense and cpPDVwithout start codon). All constructs were tested in a PDV host model, Nicotiana benthamiana, and extensive molecular characterization and controlled infections were performed on transformants and their progenies. Transgenic plants expressing the coat protein RNA were able to block the proliferation of a PDV isolate sharing only 91% homology with the isolate used for cpPDV cloning, as evaluated by DAS-ELISA on newly developed leaves. With cp expression, the blockage of PDV proliferation in newly developed leaves was only achieved with the construct cpPDV Mutated, where the coat protein has a substitution in the 14th aa residue, with arginine replaced by alanine. This result points to a possible role of the mutated amino acid in the virus ability to replicate and proliferate. This work reveals the possibility of achieving protection against PDV through either coat protein RNA or mutated cp sequence.


Annals of the Rheumatic Diseases | 2011

Caspase-1 is active since the early phase of rheumatoid arthritis

Rita Cascão; Joaquim Polido-Pereira; Helena Canhão; Ana Rodrigues; Márcio Navalho; Helena Raquel; Ana Filipa Mourão; C. Resende; João Eurico Fonseca; Luis F. Moita

Background We have previously reported an increase in interleukin (IL)-1β levels in very recent onset arthritis. Therefore, molecular mechanisms that regulate IL-1β secretion, such as caspase-1 activation, might play a relevant role in arthritis onset and progression. Objectives Our main goal was to evaluate caspase-1 state of activation in early polyarthritis and established rheumatoid arthritis (RA) patients. Materials and methods Blood samples were collected from 12 untreated early polyarthritis patients, 12 established RA patients and 10 healthy controls. Caspase-1 activity was assessed using a carboxyfluorescein FLICA detection kit. Results We found that both early polyarthritis and established RA patients have higher active caspase-1 levels. Surprisingly, caspase-1 activation levels in patient cells remain unchanged when cells were stimulated with Escherichia coli and ATP, whereas in control cells caspase-1 levels increased after stimulation. We observed no significant differences when comparing early polyarthritis with established RA samples. However, in RA patients with higher disease activity the proportion of active caspase-1 is higher. Conclusions Our results suggest that leucocytes in both early polyarthritis and established RA patients have high baseline levels of activated caspase-1, which cannot be significantly increased after stimulation. Altogether, our data supports the hypothesis that caspase-1 is activated in early arthritis.


Journal of Translational Medicine | 2011

Drugs that simultaneously down-regulate IL-1β and TNF secretion significantly reduce inflammation in a rat model of antigen-induced arthritis

Rita Cascão; Bruno Vidal; Helena Raquel; Vineet Gupta; João Eurico Fonseca; Luis F. Moita

We have previously reported an increase in interleukin (IL)-1β levels and a continuous activation of caspase-1 in rheumatoid arthritis (RA) patients in the early phase of the disease. This result suggests that drugs targeting IL-1β regulatory pathways, in addition to tumor necrosis factor (TNF), may constitute promising therapeutic agents in early RA. We have recently used a THP-1 macrophage-like cell line to screen 2320 compounds for those which down-regulate IL-1β and TNF secretion. Gambogic acid, celastrol and pristimerin were three of the most promising therapeutic candidates identified in that study.


Clinical and Experimental Rheumatology | 2012

Caspase-1 is active since the early phase of rheumatoid arthritis.

Rita Cascão; Joaquim Polido-Pereira; Helena Canhão; A Rodrigues; Márcio Navalho; Helena Raquel; Neves-Costa A; Ana Filipa Mourão; C. Resende; da Silva Ja; João Eurico Fonseca; Luis F. Moita

Collaboration


Dive into the Helena Raquel's collaboration.

Top Co-Authors

Avatar

Luis F. Moita

Instituto Gulbenkian de Ciência

View shared research outputs
Top Co-Authors

Avatar

Ana Neves-Costa

Instituto de Medicina Molecular

View shared research outputs
Top Co-Authors

Avatar

João Eurico Fonseca

Instituto de Medicina Molecular

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Catarina Moita

Instituto de Medicina Molecular

View shared research outputs
Top Co-Authors

Avatar

Vineet Gupta

Rush University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Bruno Vidal

Instituto de Medicina Molecular

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ana Filipa Mourão

Instituto de Medicina Molecular

View shared research outputs
Top Co-Authors

Avatar

Helena Canhão

Universidade Nova de Lisboa

View shared research outputs
Researchain Logo
Decentralizing Knowledge